These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25144771)

  • 1. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.
    Farrow AL; Rachakonda G; Gu L; Krendelchtchikova V; Nde PN; Pratap S; Lima MF; Villalta F; Matthews QL
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3089. PubMed ID: 25144771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease.
    Matthews QL; Farrow AL; Rachakonda G; Gu L; Nde P; Krendelchtchikov A; Pratap S; Sakhare SS; Sabbaj S; Lima MF; Villalta F
    Pathog Immun; 2016; 1(2):214-233. PubMed ID: 27709126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.
    Farrow AL; Peng BJ; Gu L; Krendelchtchikov A; Matthews QL
    Viruses; 2016 Mar; 8(3):78. PubMed ID: 26978385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection.
    Miyahira Y; Takashima Y; Kobayashi S; Matsumoto Y; Takeuchi T; Ohyanagi-Hara M; Yoshida A; Ohwada A; Akiba H; Yagita H; Okumura K; Ogawa H
    Infect Immun; 2005 Nov; 73(11):7356-65. PubMed ID: 16239534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
    Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
    J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
    Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
    Front Immunol; 2020; 11():1279. PubMed ID: 32695105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.
    Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Galler R; Bonaldo MC
    Virol J; 2011 Mar; 8():127. PubMed ID: 21418577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.
    Garg N; Tarleton RL
    Infect Immun; 2002 Oct; 70(10):5547-55. PubMed ID: 12228281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.
    Barbosa RP; Filho BG; Dos Santos LI; Junior PA; Marques PE; Pereira RV; Cara DC; Bruña-Romero O; Rodrigues MM; Gazzinelli RT; Machado AV
    PLoS One; 2013; 8(4):e61795. PubMed ID: 23637908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
    Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
    PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
    Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
    Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Farrow AL; Derdeyn CA; Matthews QL
    Virology; 2016 Jan; 487():75-84. PubMed ID: 26499044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy.
    Gu L; Krendelchtchikova V; Krendelchtchikov A; Oster RA; Fujihashi K; Matthews QL
    Virol J; 2014 Jun; 11():112. PubMed ID: 24935650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi.
    Wrightsman RA; Manning JE
    Vaccine; 2000 Jan; 18(14):1419-27. PubMed ID: 10618540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.
    Serna C; Lara JA; Rodrigues SP; Marques AF; Almeida IC; Maldonado RA
    Vaccine; 2014 Jun; 32(28):3525-32. PubMed ID: 24793944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.
    Wizel B; Garg N; Tarleton RL
    Infect Immun; 1998 Nov; 66(11):5073-81. PubMed ID: 9784506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.
    Fralish BH; Tarleton RL
    Vaccine; 2003 Jun; 21(21-22):3070-80. PubMed ID: 12798651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
    Bhatia V; Garg NJ
    Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
    Fonseca JA; Cabrera-Mora M; Kashentseva EA; Villegas JP; Fernandez A; Van Pelt A; Dmitriev IP; Curiel DT; Moreno A
    PLoS One; 2016; 11(4):e0154819. PubMed ID: 27128437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.